New era in the war on cancer," is the somewhat over-hyped headline on the front of the Daily Mail. The new era refers to the use of immunotherapy – using drugs to coax the immune system into attacking cancerous cells while leaving healthy cells unharmed.
MRV Research
Sub-stage specific surveillance imaging detects relapses in melanoma
CHICAGO — Disease sub-stage specific PET imaging effectively detected relapses in stage III melanoma, according to findings presented at the ASCO Annual Meeting.
Findings support wider excision margins in melanoma
A surgical excision margin of 3 cm yielded significantly improved disease-specific survival but not OS in a cohort of patients with high-risk melanoma, according to findings presented at the ASCO Annual Meeting.
Frontline Nivolumab Regimens Significantly Improve PFS Versus Ipilimumab in Melanoma
Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival (PFS) versus ipilimumab alone in patients with advanced melanoma, according to results from the phase III CheckMate-067 trial. The greatest benefit was seen with the combination regimen, which reduced the risk of progression by 58% and 26% (nonsignificant) compared with single-agent ipilimumab and nivolumab, respectively. The results also showed that the combination is more effective than either agent alone in PD-L1–negative patients.